Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Armodafinil Treatment (150 mg) in Improving Clinical Condition Late in the Shift and in Improving Functional and Patient-Reported Outcomes in Adult Patients With Excessive Sleepiness Associated With Shift Work Disorder
Sponsor: Cephalon
This PHASE4 trial investigates Excessive Sleepiness and is currently completed. Cephalon leads this study, which shows 8 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2022 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jan 2022 [monthly]
Completed PHASE4
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Mar 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cephalon
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Atlanta, United States, Austin, United States, Beachwood, United States, Brandon, United States, Brighton, United States, Broomall, United States, Burlingame, United States, Chevy Chase, United States, Chicago, United States, Cincinnati, United States and 49 more location s